Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, LongeVC appears to focus on life sciences and healthtech companies leveraging artificial intelligence and data analytics, with particular emphasis on longevity and drug discovery applications. Recent portfolio suggests investment activity across series-a through growth stages with typical check sizes between €1.5M and €3.0M. The investor's geographic base in Switzerland and sector concentration indicate a specialized thesis around computational biology and aging-related technologies.
Generated 8 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from LongeVC's website.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.